Program in Heart Failure and Transplantation
Our Program Heart transplantation is an important treatment that should be considered for patients who would otherwise not survive. The Program in Heart Failure and Transplantation at the Strong Heart and Vascular Center is committed to offering your patients an individualized treatment plan that will enable them to enjoy the best possible quality of life. For many patients, heart transplant dramatically improves their outcome. We have been offering heart transplantation as one of our heart failure treatments since 2001. Our program has achieved outstanding survival rates on par with other leading transplantation centers nationwide. As the only active program in New York State outside of the New York City area, we offer patients the opportunity to stay close to home, near their support network of family and friends, for the entire transplantation process. Our program is approved by the United Network for Organ Sharing (UNOS) and compliments the other transplant services long offered at Strong. Strong is recognized as a UNOS transplant center for pediatric and adult liver, intestine, kidney, and kidney/pancreas transplantation. We first began offering transplantation services in 1966 for kidney.
Training Facilities
- Ongoing training on new technology
- Outpatient clinic
- Procedure room
- Cardiopulmonary exercise testing lab
- Cardiovascular ICU (7-1600)
- Heart Failure/Transplant/ VAD Step-Down Unit (7-3400)
Annual Volumes of Patients/Procedures, etc.
- 21 Heart Transplants in 2004
- In 2004, The Program in Heart Failure and Transplantation received over 200 patient referrals.
- The Program follows over 300 Heart Failure patients, 30+ pre-transplant, 77 post-transplant patients
- Implanted 27 Ventricular Assist Devices in 2004
Current and Previous Research Efforts
- HF-ACTION: For Heart failure and A Controlled Trial Investigating Outcomes of Exercise Training
Primary Investigator: Leway Chen, M.D., M. P.H.
Years conducted April 2004-April 2009
- LUNAR: a 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phage IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes
Primary Investigator: John Bisognano, M.D.
Years Conducted: November 2004-December 2005
- WARCEF: Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction.
Primary Investigator: John Bisognano, M.D.
Years Conducted December 2002-September 2005
- COMPS: Cardiovascular Outcomes Monitoring Program at Strong
Primary Investigator: Leway Chen, M.D., M.P. H.
Years Conducted: 2004-Ongoing
- NESIRITIDE/VO2: Prospective, nonblinded study to investigate the potential benefit of nesiritide (Natrecor) in improving exercise capacity in patients with heart failure
Primary Investigator: Leway Chen, M.D., M.P.H.
Years Conducted: 2004-Ongoing
- Pivotal Study: Heartmate II:
Primary Investigator: H. Todd Massey, M.D.
Years Conducted: 2004-Ongoing
|